| Literature DB >> 21887116 |
Kathryn Curtis1, Anna Osadchuk, Joel Katz.
Abstract
OBJECTIVES: Fibromyalgia (FM) is a chronic condition characterized by widespread musculoskeletal pain, fatigue, depression, and hypocortisolism. To date, published studies have not investigated the effects of yoga on cortisol in FM. This pilot study used a time series design to evaluate pain, psychological variables, mindfulness, and cortisol in women with FM before and after a yoga intervention.Entities:
Keywords: cortisol; fibromyalgia; pain; psychological variables; yoga
Year: 2011 PMID: 21887116 PMCID: PMC3160832 DOI: 10.2147/JPR.S22761
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Participant flow through the course of the study.
Figure 2Order and time sequence of data collection. The information session was held seven days before the yoga program began. Saliva samples for cortisol analysis were collected on the two days before and the two days after the yoga program, for a total of four days. The yoga program ran for 8 weeks (2 classes/week) and the follow-up session took place two days after the final day of saliva collection. Questionnaires concerning pain and related variables, psychological factors and mindfulness were evaluated at three time points (T1, T2 and T3).
Demographic and clinical variables at baseline (N = 22)
| Age | 47.4 (13.73) |
| Height | 163.58 (8.43) |
| Weight (kg) | 70.98 (18.89) |
| Body mass index (BMI) | 26.48 (6.27) |
| Years since diagnosis | 13.16 (8.55) |
| Race/ethnicity | |
| African Canadian | 1 (4.5%) |
| South Asian | 1 (4.5%) |
| East Asian | 1 (4.5%) |
| Middle Eastern/north | 1 (4.5%) |
| Caucasian | 16 (72.7%) |
| Hispanic | 1 (4.5%) |
| West Indian | 1 (4.5%) |
| Socioeconomic class | |
| High | 0 (0.0%) |
| Middle-high | 1 (4.5%) |
| Middle | 13 (59.1%) |
| Middle-low | 2 (9.1%) |
| Low | 5 (22.7%) |
| Employed | 8 (36.4%) |
| Level of education | |
| Grade-school | 1 (4.5%) |
| High-school | 3 (13.6%) |
| University/college | 14 (63.6%) |
| Post-graduate school | 4 (18.2%) |
| Smokes cigarettes | 4 (18.2%) |
| Major life event in past year | 11 (50.0%) |
| Presence of other ongoing pain problems | 16 (72.6%) |
| Fibromyalgia pain frequency | |
| Daily | 15 (68.2%) |
| Weekly | 4 (18.2%) |
| Monthly | 0 |
| Other | 3 (13.6%) |
| Average pain intensity | |
| Mild | 4 (18.2%) |
| Moderate | 9 (40.9%) |
| Severe | 9 (40.9%) |
Pain medications and treatments previously or currently used (N = 22)
| Pharmacological medications | 18 | (81.8) |
| Opioid based medications | 9 | (40.9) |
| Non-steroidal anti-inflammatory drugs | 10 | (45.5) |
| Anti-convulsant drugs | 4 | (18.2) |
| Acetaminophen | 8 | (36.4) |
| Antidepressants | 3 | (13.6) |
| Natural health products | 18 | (81.8) |
| Supplements and vitamins, marijuana, herbs, homeopathy, essential oils, etc | ||
| Physical approaches | 20 | (90.9) |
| Massage, acupuncture, Tai Chi, physiotherapy, chiropracty, craniosacral treatment, etc | ||
| Psychological approaches | 17 | (77.3) |
| Meditation, breathing exercises, psychotherapy, distraction, relaxation, religion, hypnosis, etc | ||
| Medical interventions | 6 | (27.3) |
| Cortisone, anesthetic injections |
Mean (SD) values for pain, psychological and mindfulness variables across time (N = 19)
| NRS-I | 5.21 (2.80) | 4.68 (3.00) | 4.68 (2.75) | ns |
| NRS-U | 5.33 (2.89) | 4.50 (3.37) | 4.67 (2.63) | ns |
| SLAP | 11.89 (5.50) | 12.39 (5.27) | 12.83 (5.140) | ns |
| FFMQ-total[ | 120.21 (21.80) | 126.47 (22.53) | 130.63 (20.82) | 0.02 |
| FFMQ-observing | 29.32 (4.77) | 29.61 (4.75) | 30.89 (4.22) | ns |
| FFMQ-describing[ | 23.58 (7.02) | 23.87 (7.87) | 25.84 (7.31) | 0.03 |
| FFMQ-acting with awareness | 18.13 (5.04) | 19.26 (4.91) | 20.08 (4.80) | ns |
| FFMQ-non-judging | 23.84 (5.52) | 25.55 (5.01) | 25.37 (5.51) | ns |
| FFMQ-non-reactivity[ | 19.16 (5.48) | 21.53 (4.59) | 22.00 (4.61) | 0.01 |
| PDI | 38.14 (17.17) | 36.83 (16.31) | 33.81 (14.43) | ns |
| PCS-total | 25.33 (14.77) | 21.67 (16.26) | 20.40 (17.01) | 0.04 |
| PCS-helplessness | 11.50 (7.43) | 9.72 (7.47) | 9.28 (7.83) | 0.04 |
| PCS-magnification | 5.94 (3.45) | 4.81 (3.51) | 4.69 (3.18) | ns |
| PCS-rumination | 8.67 (4.83) | 7.67 (5.72) | 7.44 (5.89) | ns |
| CPAQ-total[ | 60.47 (23.43) | 65.44 (19.20) | 69.50 (22.93) | 0.003 |
| CPAQ-activity engagement[ | 37.86 (15.13) | 43.83 (11.58) | 44.75 (14.57) | 0.001 |
| CPAQ-pain willingness | 22.61 (10.35) | 21.61 (9.53) | 24.75 (10.72) | 0.04 |
| MPQ-SF-2-total | 4.03 (1.86) | 3.38 (1.73) | 3.62 (2.14) | ns |
| MPQ-SF-2-continuous pain[ | 5.18 (1.72) | 4.44 (2.03) | 4.43 (2.14) | 0.03 |
| MPQ-SF-2-intermittent pain | 3.32 (2.18) | 2.57 (2.02) | 3.40 (2.45) | ns |
| MPQ-SF-2-neuropathic pain | 3.51 (2.10) | 3.20 (1.85) | 3.01 (2.25) | ns |
| MPQ-SF-2-affective pain | 4.26 (2.45) | 3.38 (2.49) | 3.64 (2.72) | ns |
| HADS-A | 10.83 (4.40) | 11.50 (5.06) | 9.78 (4.47) | ns |
| HADS-D | 9.00 (4.54) | 8.65 (4.65) | 7.47 (4.26) | ns |
Note: Huynh–Feldt adjusted F-tests for significant main effects of time were conducted for all self-reported measures. Numeric rating scale for pain intensity: NRS-I; numeric rating scale for unpleasantness: NRS-U; Sum of Local Areas of Pain: SLAP; Five Facet Mindfulness Questionnaire: FFMQ; Pain Disability Index: PDI, Pain Catastrophizing Scale: PCS, Chronic Pain Acceptance Questionnaire: CPAQ; McGill Pain Questionnaire short form 2: MPQ-SF-20; Hospital Anxiety and Depression-Depression Scale: HADS-D, Hospital Anxiety and Depression Scale-Anxiety: HADS-A.
p < 0.05 for T1 vs T2;
p < 0.05 for T1 vs T3; and
p < 0.05 for T2 vs T3.
Figure 3Pre- and post-intervention means for salivary cortisol levels (μg/dL), averaged across the two sampling days. S1, S2, S3 indicate first sample upon wakening, second sample 30 minutes after awakening, and third sample before sleep, respectively. Two outliers from the raw data that had z-scores of greater than ±3 were adjusted to values that were ±2 standard deviations from the mean of that measurement.